Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mixed phenotype acute leukemia is described as an acute leukemia of ambiguous lineage. It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage. The abbreviation MPAL is listed as a synonym. Prevalence is unknown in this packet.
Individual clinical features, phenotype terms, and age of onset are not itemized in this packet. The condition is characterized at the cellular level by blasts of more than one lineage or blasts co-expressing markers of more than one lineage, and details of its clinical presentation are unknown from this packet.
The genetic basis and mode of inheritance are not certified in this packet. The packet lists three related subtypes: mixed phenotype acute leukemia with t(v;11q23.3), acute biphenotypic leukemia, and mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2). Subtypes are named by chromosomal translocation, but the packet supplies no further mechanism information.
Diagnostic methods and diagnostic criteria are not certified in this packet. The definition describes the identifying feature as separate blast populations of more than one lineage, or a single blast population co-expressing markers of more than one lineage.
The packet does not list approved treatments or management guidance for mixed phenotype acute leukemia. Investigational approaches, including drug, biologic, procedural, and transplant-related studies, appear among the trial records described under research.
46 trials found
Prognosis is not certified in this packet.
Numerous certified active trial records are present, including studies of drug therapy, biologic therapy, and transplantation, some enrolling people with other leukemias or blood cancers alongside this condition. Examples include NCT05327894, a phase 3 treatment protocol for infants under one year with certain acute lymphoblastic leukemia or mixed phenotype acute leukemia (recruiting); NCT07356154, a phase 1 study of two investigational agents in people with leukemia (recruiting); and NCT06575296, a phase 1 study in acute leukemia after allogeneic stem cell transplant (recruiting). Active clinical trials for this condition are listed on ClinicalTrials.gov.
Data assembled from 4 of 12 sources · Last updated Nov 18, 2026, 8:42 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning mixed phenotype acute leukemia
Updated Sep 2, 2026
A multi-center case series investigates clinical outcomes and molecular features of CEBPA-mutated mixed phenotype acute leukemia (MPAL). The findings contribute to understanding the disease's biology and potential treatment strategies.
A rare case report details mixed phenotype acute leukemia presenting symptoms similar to adult-onset Still's disease in a pregnant female. This case highlights the diagnostic challenges and the need for awareness of overlapping symptoms in rare diseases.